Literature DB >> 20111819

[Epidemiology of varicella in spain pre-and post-vaccination periods].

Isabel Peña-Rey1, María Victoria Martínez de Aragón, Ana Villaverde Hueso, Monserrat Terres Arellano, Enrique Alcalde Cabero, Berta Suárez Rodríguez.   

Abstract

BACKGROUND: Varicella virus can cause two different diseases: chickenpox and herpes zoster. In 2005 varicella vaccine has been introduced in the Spanish national vaccination schedule for 10-14 years old non-immune people, in order to reduce the severity of the disease. In 2007 a new surveillance protocol with aggregate data for chickenpox and herpes zoster was approved in order to detect any change in age distribution, severity and complications of the chickenpox and herpes zoster cases. The aim of this study is to know the burden of diseases (in the last ten years).
METHODS: Number of cases, hospitalization and incidence for chickenpox and herpes zoster were study for two periods 1997-2003 and 2005-2007. Analysis for 1996-2007 fatal cases was done too. We decided to remove year 2004 because the extremely high chickenpox incidence registered. SOURCES OF DATA: RENAVE (Spanish Surveillance Network), Spanish hospital surveillance system (CMBD), and mortality registries.
RESULTS: Chickenpox incidence decreased since 2005, but an increasing trend was detected in hospitalisation with an average of 1,311 hospitalizations every year. For the 32%-36% of hospitalized cases, the main diagnosis was not chickenpox. 4-14 deaths per year have been detected; 80% of them were older than 14 years. Annual rate of herpes zoster hospitalization was 2.5 per 100,000 inhabitants, similar in both sexes. Case fatality rate per year was 0.31 per million inhabitants. No significant changes were detected in age and sex in complicated cases between the two periods. 88% of chickenpox cases were younger than 15 years old and 64% of herpes zoster older than 50 years in 2007.
CONCLUSIONS: Chickenpox has been decreasing during 2005-2007 in Spain. The impact of vaccination is difficult to asses, because of a peak registered in 2004 but also because the lack of vaccination coverage information for this period and the case-data information is available only for the last year.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20111819     DOI: 10.1590/s1135-57272009000500012

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  4 in total

1.  Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.

Authors:  Alba González-Escalada; Laura García-García; Pablo Viguera-Ester; Patricia Marín-García; Jesus García; Angel Gil-de-Miguel; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

2.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

3.  Economic burden of varicella in Europe in the absence of universal varicella vaccination.

Authors:  Manjiri Pawaskar; Estelle Méroc; Salome Samant; Elmira Flem; Goran Bencina; Margarita Riera-Montes; Ulrich Heininger
Journal:  BMC Public Health       Date:  2021-12-21       Impact factor: 3.295

4.  Herpes zoster surveillance using electronic databases in the Valencian Community (Spain).

Authors:  Nuria Morant-Talamante; Javier Diez-Domingo; Sergio Martínez-Úbeda; Joan Puig-Barberá; Sara Alemán-Sánchez; Lina Pérez-Breva
Journal:  BMC Infect Dis       Date:  2013-10-05       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.